Advertisement
Screener

DYADIC INTERNATIONAL INC (DYAI) Costs and Expenses

2.8 / 5 stars · 68/120 Roast Me

DYADIC INTERNATIONAL INC Costs and Expenses

DYADIC INTERNATIONAL INC (DYAI) reported Costs and Expenses of $3.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:CostsAndExpenses · last filed 2026-08-12

  • DYADIC INTERNATIONAL INC costs and expenses for the quarter ending 2026-06-30 was $3.02M, a 11.86% increase year-over-year.
  • DYADIC INTERNATIONAL INC costs and expenses for the quarter ending 2026-03-31 was $3.01M, a 25.78% increase year-over-year.
  • DYADIC INTERNATIONAL INC costs and expenses for the quarter ending 2025-12-31 was $2.10M, a 10.48% decline year-over-year.
  • DYADIC INTERNATIONAL INC costs and expenses for the quarter ending 2025-09-30 was $3.09M, a 43.05% increase year-over-year.
  • DYADIC INTERNATIONAL INC costs and expenses for fiscal 2025 was $10.28M, a 9.44% increase from fiscal 2024.
  • DYADIC INTERNATIONAL INC costs and expenses for fiscal 2024 was $9.40M, a 15.57% decline from fiscal 2023.
  • DYADIC INTERNATIONAL INC costs and expenses for fiscal 2023 was $11.13M, a 15.02% decline from fiscal 2022.
  • DYADIC INTERNATIONAL INC costs and expenses for fiscal 2022 was $13.10M, a 23.56% decline from fiscal 2021.
Period endCosts and Expenses 3 monthCosts and Expenses 3 month as first filedCosts and Expenses 6 monthCosts and Expenses 9 monthCosts and Expenses 12 month
2026-06-30$3.02M
10-Q · filed 2026-08-12
$6.03M
10-Q · filed 2026-08-12
$8.13M
derived: sum of 3 quarters · filed 2026-08-12
$11.22M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$3.01M
10-Q · filed 2026-05-13
$5.12M
derived: sum of 2 quarters · filed 2026-05-13
$8.21M
derived: sum of 3 quarters · filed 2026-05-13
$10.90M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$2.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$5.19M
derived: sum of 2 quarters · filed 2026-03-25
$7.89M
derived: sum of 3 quarters · filed 2026-08-12
$10.28M
10-K · filed 2026-03-25
2025-09-30$3.09M
10-Q · filed 2025-11-12
$5.79M
derived: sum of 2 quarters · filed 2026-08-12
$8.18M
10-Q · filed 2025-11-12
$10.53M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$2.70M
10-Q · filed 2026-08-12
$5.09M
10-Q · filed 2026-08-12
$7.44M
derived: sum of 3 quarters · filed 2026-08-12
$9.60M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$2.40M
10-Q · filed 2026-05-13
$4.74M
derived: sum of 2 quarters · filed 2026-05-13
$6.90M
derived: sum of 3 quarters · filed 2026-05-13
$9.33M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$2.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$4.51M
derived: sum of 2 quarters · filed 2026-03-25
$6.94M
derived: sum of 3 quarters · filed 2026-03-25
$9.40M
10-K · filed 2026-03-25
2024-09-30$2.16M
10-Q · filed 2025-11-12
$4.59M
derived: sum of 2 quarters · filed 2025-11-12
$7.05M
10-Q · filed 2025-11-12
$9.90M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$2.43M
10-Q · filed 2025-08-13
$4.89M
10-Q · filed 2025-08-13
$7.74M
derived: sum of 3 quarters · filed 2025-08-13
$9.86M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$2.46M
10-Q · filed 2025-05-14
$5.32M
derived: sum of 2 quarters · filed 2025-05-14
$7.43M
derived: sum of 3 quarters · filed 2025-05-14
$10.56M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$2.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26
$4.97M
derived: sum of 2 quarters · filed 2025-03-26
$8.10M
derived: sum of 3 quarters · filed 2025-03-26
$11.13M
10-K · filed 2025-03-26
2023-09-30$2.12M
10-Q · filed 2024-11-12
$5.24M
derived: sum of 2 quarters · filed 2024-11-12
$8.27M
10-Q · filed 2024-11-12
$11.26M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$3.13M
10-Q · filed 2024-08-13
$6.16M
10-Q · filed 2024-08-13
$9.14M
derived: sum of 3 quarters · filed 2024-08-13
$11.88M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$3.03M
10-Q · filed 2024-05-14
$6.01M
derived: sum of 2 quarters · filed 2024-05-14
$8.75M
derived: sum of 3 quarters · filed 2024-05-14
$12.73M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$2.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
$5.73M
derived: sum of 2 quarters · filed 2024-03-28
$9.70M
derived: sum of 3 quarters · filed 2024-03-28
$13.10M
10-K · filed 2024-03-28
2022-09-30$2.74M
10-Q · filed 2023-11-08
$6.72M
derived: sum of 2 quarters · filed 2023-11-08
$10.11M
10-Q · filed 2023-11-08
$14.64M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30$3.98M
10-Q · filed 2023-08-09
$7.37M
10-Q · filed 2023-08-09
$11.90M
derived: sum of 3 quarters · filed 2023-08-09
$15.92M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31$3.39M
10-Q · filed 2023-05-10
$3.39B
10-Q · filed 2022-05-12
$7.92M
derived: sum of 2 quarters · filed 2023-05-10
$11.94M
derived: sum of 3 quarters · filed 2023-05-10
$16.74M
derived: sum of 4 quarters · filed 2023-05-10
2021-12-31$4.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29
$8.55M
derived: sum of 2 quarters · filed 2023-03-29
$13.35M
derived: sum of 3 quarters · filed 2023-03-29
$17.13M
10-K · filed 2023-03-29
2021-09-30$4.02M
10-Q · filed 2022-11-10
$8.82M
derived: sum of 2 quarters · filed 2022-11-10
$12.60M
10-Q · filed 2022-11-10
$3.79B
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30$4.80M
10-Q · filed 2022-08-10
$8.59M
10-Q · filed 2022-08-10
$3.79B
derived: sum of 3 quarters · filed 2022-08-10
$3.79B
derived: sum of 4 quarters · filed 2022-08-10
2021-03-31$3.78B
10-Q · filed 2022-05-12
$3.78M
10-Q · filed 2021-05-13
$3.78B
derived: sum of 2 quarters · filed 2022-05-12
$3.79B
derived: sum of 3 quarters · filed 2022-05-12
$3.79B
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$2.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29
$5.61M
derived: sum of 2 quarters · filed 2022-03-29
$8.93M
derived: sum of 3 quarters · filed 2022-03-29
$11.63M
10-K · filed 2022-03-29
2020-09-30$2.99M
10-Q · filed 2021-11-10
$6.31M
derived: sum of 2 quarters · filed 2021-11-10
$9.01M
10-Q · filed 2021-11-10
$11.38M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$3.32M
10-Q · filed 2021-08-12
$6.02M
10-Q · filed 2021-08-12
$8.39M
derived: sum of 3 quarters · filed 2021-08-12
$10.79M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31$2.70M
10-Q · filed 2021-05-13
$5.07M
derived: sum of 2 quarters · filed 2021-05-13
$7.47M
derived: sum of 3 quarters · filed 2021-05-13
$10.82M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31$2.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30
$4.77M
derived: sum of 2 quarters · filed 2021-03-30
$8.12M
derived: sum of 3 quarters · filed 2021-03-30
$10.96M
10-K · filed 2021-03-30
2019-09-30$2.40M
10-Q · filed 2020-11-12
$5.75M
derived: sum of 2 quarters · filed 2020-11-12
$8.59M
10-Q · filed 2020-11-12
$11.05M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30$3.35M
10-Q · filed 2020-08-13
$6.20M
10-Q · filed 2020-08-13
$8.65M
derived: sum of 3 quarters · filed 2020-08-13
$10.69M
derived: sum of 4 quarters · filed 2020-08-13
2019-03-31$2.84M
10-Q · filed 2020-05-14
$5.30M
derived: sum of 2 quarters · filed 2020-05-14
$7.34M
derived: sum of 3 quarters · filed 2020-05-14
$9.32M
derived: sum of 4 quarters · filed 2020-05-14
2018-12-31$2.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30
$4.50M
derived: sum of 2 quarters · filed 2020-03-30
$6.47M
derived: sum of 3 quarters · filed 2020-03-30
$8.89M
10-K · filed 2020-03-30
2018-09-30$2.04M
10-Q · filed 2019-11-13
$4.02M
derived: sum of 2 quarters · filed 2019-11-13
$6.44M
10-Q · filed 2019-11-13
2018-06-30$1.98M
10-Q · filed 2019-08-13
$4.39M
10-Q · filed 2019-08-13
2018-03-31$2.41M
10-Q · filed 2019-05-09
2017-12-31$7.89M
10-K · filed 2019-03-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
BioCardia, Inc. (BCDA)United States$0.016B
Passage BIO, Inc. (PASG)United States$0.015B-0.43
Pluri Inc. (PLUR)$0.014B
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37
IN8BIO, INC. (INAB)United States$0.012B-0.76
Estrella Immunopharma, Inc. (ESLA)United States$0.020B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23